Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Irinotecan + PM54 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Irinotecan | Camptosar | CPT-11 | TOPO1 inhibitor 11 | Camptosar (irinotecan) inhibits Topoisomerase-I activity, resulting in inhibition of DNA replication, and potentially leading to cell death and is indicated as a component of first-line therapy in combination with 5-fluorouracil and leucovorin for patients with metastatic or recurrent colorectal carcinoma (FDA.gov). |
| PM54 | PM-54|PM 54 | PM54 is a lurbinectedin-derived transcriptional inhibitor which impairs mRNA synthesis, potentially resulting in enhanced antitumor immune response and inhibition of tumor growth (PMID: 39709435). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07839819 | Phase Ib/II | Irinotecan + PM54 Doxorubicin + PM54 | Study of PM54 in Combination With Cytotoxic and Targeted Agents in Adult Participants With Advanced Malignancies | Not yet recruiting | USA | FRA | DEU | 1 |